Sunday, September 20, 2009

Panvax H1N1 Approval For Registration For Use in Australia by Therapeutic Goods Administration

18/09/2009 -CSL Biotherapies, a subsidiary of CSL Limited, Australia's leading biopharmaceutical company, can today confirm that its vaccine against the pandemic (H1N1) 200 influenza or 'swine flu' has been approved registration for use in people aged 10 years and over.

The details can be read here.

No comments: